Levofloxacin for the treatment of community-acquired pneumonia

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 725-742

  Lynch III, Joseph P ^a   File Jr , Thomas M ^b   Zhanel, George G ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Community acquired pneumonia; Fluoroquinolones; Levofloxacin; Respiratory infection

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ACUTE HEART INFARCTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; CONGESTIVE HEART FAILURE; CONSTIPATION; COST CONTROL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRURITUS; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TASTE DISORDER; THRUSH; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; OFLOXACIN; PNEUMONIA;

EID: 33845454335     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14737140.4.5.725     Document Type: Article

References (87)

1. Zhanel GG, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62(1), 13-59 (2002).
2. Zhanel GG, Waltky A, Laing N et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 49, 807-812 (2003).
3. Ball P, Stahlmann R, Kubin R et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin. Ther. 26, 940-950 (2004).
4. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700 (1994).
5. Domagala J. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33, 685-706 (1994).
6. Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 49, 16-28 (1995).
7. Zhanel GG, Walkty A, Vercaigne L et al. The new fluoroquinolones: a critical review. Can. J. Infect. Dis. 10, 207-238 (1999).
8. Andersson MI, MacCowan AP. Development of the quinolones. J. Antimicrob. Chemother. 1, 1-11 (2003).
9. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol. 1(5), 459-463 (2001).
10. O'Donnel JA, Gelone SP. The newer fluoroquinolones. Infect. Dis. Clinics. N. Am. 18, 691-716 (2004).
11. Smith HJ, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J. Antimicrob. Chemother 49, 893-895 (2002).
12. Leggett LD, Saravolatz J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Rev. Anti-infect. Agents 37, 1210-1215 (2003).
13. Zhanel GG, Hoban DJ, Schurek K et al. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 24, 529-535 (2004).
14. Smith HJ, Walters M, Hisanaga T et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents. Chemother. 48(10), 3954-3958 (2004).
15. Schmitz FJ, Higgins PG, Mayer S et al. Activity of quinolones against Gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 21, 647-659 (2002).
16. Tillotson GS, File TM. Gemifloxacin: a new potent fluoroquinolone for the therapy of lower respiratory tract infections. Exp. Rev. Anti-infect. Ther. 2(6), 831-843 (2004).
17. Soussy CJ, Nguyen J, Goldstein F et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicenter study. Clin. Microbiol. Infect. 9(10), 997-1005 (2003).
18. Bouchillon SK, Johnson JL. In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study. Int. J. Antimicrob. Agents 23, 181-196 (2004).
19. Casellas JM, Tome G. Comparative in vitro activity of levofloxacin against isolates of bacteria from adult patients with community-aquired lower respiratory tract infections. J. Antimicrob. Chemother. 43, 37-42 (1999).
20. Diekema DJ, Rolston KV. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organims isolated at 10 cancer-treatment centers. Diagn. Microbiol. Infect. Dis. 34, 37-43 (1999).
21. Edmiston CE, Seabrook GR. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother. 48, 1012-1016 (2004).
22. Fung-Tome J, Minassian B, Kolek B et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. 45, 437-446 (2000).
23. Keller N, Smollen G, Davidson Y et al. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics. J. Antimicrob. Chemother. 43, 1-3 (1999).
24. King A, May J, French G et al. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 45, 1-12 (2000).
25. Montanari MP, Mingoia M, Marchetti F et al. In vitro activity of levofloxacin against gram-positive bacteria. Chemotherapy 45, 411-417 (1999).
26. Yoo BK, Triller DM, Yong CS et al. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann. Pharmacother. 38, 1226-1235 (2004).
27. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J. Antimicrob. Chemother. 45, 31-39 (2000).
28. Pong A, Thomson KS, Moland ES et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemotherapy 44, 621-627 (1999).
29. Rittenhouse SL, McCloskey J, Broskey N et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory. J. Antimicrob. Chemother. 45, 23-27 (2000).
30. Ackerman G, Schaumann R, Pless B et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 19, 228-232 (2000).
31. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41, 709-711 (1997).
32. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 1654-1659 (2001).
33. Dubois J, St-Pierre C. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn. Microbiol. Infect. Dis. 33, 261-265 (1999).
34. Edlund CS, Sabouri S, Nord CE. Comparative in vitro activity of BAY 128039 and five other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 17, 193-195 (1998).
35. Ednie LM, Jacobs MR, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Chemother. 42, 2459-2462 (1998).
36. Goldstein EJ, Citron DM, Merriam CV et al. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob. Agents Chemother. 43, 1475-1479 (1999).
37. Goldstein EJ, Citron DM, Warren Y et al. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob. Agents Chemother. 43, 2231-2235 (1999).
38. Roblin PM, Hammerschlag MR. In vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J. Antimicrob. Chemother. 44, 549-551 (1999).
39. Snydman DR, Jacobus NV, McDermott LA et al. In vitro activities of newer quinolones against bacteroides group organisms. Antimicrob. Agents Chemother. 46, 3276-3279 (2002).
40. Wexler HM, Molitoris E, Molitoris D et al. In vitro activity of levofloxacin against a selected group of anaerobic bacteric isolated from skin and soft tissue infections. Antimicrob. Agents Chemother. 42, 984-986 (1998).
41. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22, 203-221 (2003).
42. (CLSI) NCCIS. Performance standards for antimicrobial suceptibility testing: 15th informational supplement, M100-S15 CLSI. PN, USA (2005).
43. Hedberg M, Nord CE, ESCMID study group on antimicrobial resistance in anaerobic bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9, 475-488 (2003).
44. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl. 1), 19-24 (1996).
45. Rodvold K, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21, 233-252 (2001).
46. Paladino JA, Callen WA. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters. J. Antimicrob. Chemother. 51, 43-47 (2003).
47. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-12 (1998).
48. Dalhoff A. Pharmacokinetics of fluoroquinolones. J. Antimicrob. Chemother. 43, 51-59 (1998).
49. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32, 101-119 (1997).
50. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxy quinolone and its potential relationship to therapeutic efficacy. Clin. Drug Invest. 17, 365-387 (1999).
51. Gee T, Andrews JM, Ashby JP et al. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J. Antimicrob. Chemother. 47, 431-434 (2001).
52. Wise R, Andrews JM, Ashby JB et al. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J. Antimicrob. Chemother. 44, 701-704 (1999).
53. Wise R, Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43, 1508-1510 (1999).
54. Naber CK, Steghafner M, Kinzig-Schippers M et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob. Agents. Chemother. 45, 293-297 (2001).
55. Andrews J, Honeybourne D, Jevons G et al. Concentration of levofloxacin (HR 355) in the respiratory tract following a single dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 40, 573-577 (1997).
56. Andrews J, Honeybourne D, Jevons G. Penetration of BAY 12-8039 into bronchial mucosa epithelial lining. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (1998).
57. Soman A, Honeyboune D, Andrews J et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44, 835-838 (1999).
58. Simon S, Sampol E, Albanese J et al. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe brochopneumonia. Clin. Pharmacol. Ther. 43, 353-363 (2003).
59. Goodwin SD, Gallis HA, Chow AT et al. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38, 799-804 (2004).
60. Thomas KS, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42, 521-527 (1998).
61. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 43, 1118-1123 (1999).
62. Mackenzie FM,Gould IM. The post-antibiotic effect. J. Antimicrob. Chemother. 32, 519-537 (1993).
63. Blondeau JM, Xilin A, Hansen G et al. A mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45(2), 433-438 (2001).
64. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3), 147-156 (2001).
65. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993).
66. Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community acquired respiratory tract infections. Antimicrob. Agents Chemother. 45, 2793-2797 (2001).
67. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279, 125-129 (1998).
68. File TM Jr, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 33, 1965-1972 (1997).
69. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand. J. Infect. Dis. 30, 397-404 (1998).
70. Frank E, Liu J, Kinasewitz G et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther. 24, 1292-1308 (2002).
71. Erard V, Lamy O, Bochud PY, Bille J, Cometa A, Calanda T. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 23, 82-88 (2004).
72. Fogarty C, Siami G, Kohler R et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin. Infect. Dis. 38, S16-S23 (2004).
73. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128, 172-183 (2005).
74. Anzueto A, Niederman MS, Pearl J et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis. 42, 73-81 (2006).
75. Morganroth J, Dimarco J, Anzueto A et al. A randomized trial comaring the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128, 3398-3406 (2005).
76. Dunbar LM, Wunderick RG, Habib MP et al. High-dose, short course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760 (2003).
77. Short AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients ≥ 65 years with community-acquired pneumonia. Clin. Ther. 27, 1251-1259 (2005).
78. Gotfried MH, Dattani D,Riffer E et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin. Ther. 24, 736-751 (2002).
79. D'Ignazio J, Canere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia. Antimicrob. Agents Chemother. 49, 4035-4041 (2005).
80. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. J. Am. Med. Assoc. 283, 749-755 (2000).
81. Yu VL, Greenbery RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 125, 2135-2139 (2004).
82. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Francis L et al. Antimicrobial chemotherapy for legionnaries disease: levofloxacin versus macrolides. Clin. Infect. Dis. 40, 800-806 (2005).
83. Mykietiuk A, Carratal J, Fernandez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuira era: the influence of levofloxacin therapy. Clin. Infect. Dis. 40, 794-799 (2005).
84. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750 mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 20, 555-563 (2004).
85. Akpunonu B, Michaelis J, Uy CN et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin. Infect. Dis. 38(Suppl. 1), S5-S15 (2004).
86. Kahn JB, Wiesinger A, Xiang J. Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia: clinical and microbiological outcomes for patients treated with levofloxacin. Clin. Infect. Dis. 38(Suppl. 1), S24-S33 (2004).
87. Kahn JB, Bahal N, Weisinger BA, Xiang J. Cumulative clinical trial experience with levofloxacin for patients with community-acquired pneumonia-associated pneumococcal bacteremia. Clin. Infect. Dis. 38(Suppl. 1), S34-S43 (2004).